Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in USD (TTM)64.40bn
  • Net income in USD12.61bn
  • Incorporated1966
  • Employees103.61k
  • Location
    Roche Holding AGGrenzacherstrasse 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttps://www.roche.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ROG:SWX since
announced
Transaction
value
LumiraDx International LtdAnnounced29 Dec 202329 Dec 2023Announced-8.31%--
LumiraDx Group LtdAnnounced29 Dec 202329 Dec 2023Announced-8.31%295.00m
Carmot Therapeutics IncDeal completed04 Dec 202304 Dec 2023Deal completed-7.22%3.10bn
Data delayed at least 15 minutes, as of Apr 24 2024 16:19 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vertex Pharmaceuticals Incorporated9.87bn3.62bn104.65bn5.40k29.155.9427.5310.6013.8913.8937.8868.220.48282.106.571,827,630.0017.7119.9220.9323.6487.2187.6736.6835.853.78--0.0210.0010.5126.498.9646.5022.02--
Amgen Inc28.19bn6.72bn146.60bn26.70k21.9023.5013.595.2012.4912.4952.4211.640.34741.164.391,055,805.008.2810.3610.4813.0670.1675.4123.8326.511.133.150.91259.547.093.492.52-4.368.5410.04
Pfizer Inc58.50bn2.13bn149.04bn88.00k73.261.6717.612.550.35930.356610.2915.770.27611.885.29664,738.601.038.201.3010.4069.2469.343.7122.680.6935--0.44660.11-41.707.46-93.20-7.9412.213.82
Roche Holding AG (ADR)64.40bn12.61bn206.27bn103.61k15.936.2011.893.201.961.9610.015.040.65741.915.19621,618.3013.8416.1220.8425.2473.3971.4821.0522.981.0420.770.467658.80-7.210.6494-7.431.9010.01--
AbbVie Inc54.32bn4.82bn300.20bn50.00k62.3428.9022.075.532.722.7230.635.870.39724.754.851,086,360.003.566.554.738.4066.4569.748.9716.460.76389.120.851111.46-6.4410.65-59.09-3.444.0210.52
Data as of Apr 24 2024. Currency figures normalised to Roche Holding AG's reporting currency: US Dollar USD

Institutional shareholders

0.81%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Dec 202324.57m0.44%
Loomis, Sayles & Co. LPas of 18 Apr 20246.04m0.11%
Principal Global Investors LLCas of 29 Feb 20244.62m0.08%
Mairs & Power, Inc.as of 28 Mar 20242.58m0.05%
Saratoga Research & Investment Managementas of 31 Mar 20242.46m0.04%
AllianceBernstein LPas of 05 Apr 20241.85m0.03%
Parnassus Investments LLCas of 28 Mar 20241.39m0.03%
Pacer Advisors, Inc.as of 04 Apr 20241.12m0.02%
abrdn, Inc.as of 31 Dec 2023562.83k0.01%
Fidelity Management & Research Co. LLCas of 31 Jan 2024522.50k0.01%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.